Home Cart Sign in  
Chemical Structure| 14459-29-1 Chemical Structure| 14459-29-1

Structure of Hematoporphyrin
CAS No.: 14459-29-1

Chemical Structure| 14459-29-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hematoporphyrin is a substrate for affinity chromatography of heme-binding proteins.

Synonyms: Hematoporphyrin IX

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hematoporphyrin

CAS No. :14459-29-1
Formula : C34H38N4O6
M.W : 598.69
SMILES Code : O=C(O)CCC1=C2/C=C3C(CCC(O)=O)=C(C)C(/C=C(N/4)/C(C)=C(C(O)C)C4=C\C5=N/C(C(C(O)C)=C5C)=C\C(N2)=C1C)=N/3
Synonyms :
Hematoporphyrin IX
MDL No. :MFCD00005077

Safety of Hematoporphyrin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02628665 Stage I Esophageal Adenocarcin... More >>oma Stage II Esophageal Adenocarcinoma Stage III Esophageal Adenocarcinoma Stage I Esophageal Squamous Cell Carcinoma Stage II Esophageal Squamous Cell Carcinoma Stage III Esophageal Squamous Cell Carcinoma Less << Phase 3 Recruiting December 2019 China, Henan ... More >> The First Affiliated Hospital of Henan University of Science and Technology Recruiting Luoyang, Henan, China, 471003 Contact: shegan gao, doctor    0379 64811906    gsg112258@163.com    Contact: tanyou shan, master    0379 64815350    shantanyou@163.com Less <<
NCT02662504 Malignant Pleural Mesothelioma Phase 2 Completed - France ... More >> CHRU de Lille Hôpital Calmette Lille, France Less <<
NCT02082522 Hilar Cholangiocarcinoma Phase 3 Terminated(Accrual rate remain... More >>ing too low) Less << - -
NCT00118222 Brain and Central Nervous Syst... More >>em Tumors Less << Phase 3 Completed - United States, Ohio ... More >> Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5000 Less <<
NCT01770132 Acinar Cell Adenocarcinoma of ... More >>the Pancreas Duct Cell Adenocarcinoma of the Pancreas Stage III Pancreatic Cancer Less << Phase 1 Completed - United States, Indiana ... More >> IU Simon Cancer Center Indianapolis, Indiana, United States, 46202 Less <<
NCT00453336 Head and Neck Cancer ... More >> Precancerous/Nonmalignant Condition Less << Phase 2 Completed - United States, Florida ... More >> University of Miami Sylvester Comprehensive Cancer Center - Miami Miami, Florida, United States, 33136 Less <<
NCT00453336 - Completed - -
NCT01682746 Brain Tumor, Recurrent Phase 1 Recruiting April 2024 United States, Wisconsin ... More >> Children's Hospital of Wisconsin Recruiting Wauwatosa, Wisconsin, United States, 53226 Principal Investigator: Harry T Whelan, MD Less <<
NCT01506115 Hepatocellular Carcinoma ... More >> Obstructive Jaundice Less << Not Applicable Completed - Korea, Republic of ... More >> Samsung Medical Center 81 Irwon-Ro Gangnamgu Seoul, Korea, Republic of, 06351 Less <<
NCT00322699 Superficial Bladder Cancer Phase 1 Phase 2 Completed - United States, Florida ... More >> Malcom Randall NF/SG Veterans Administration Health System Gainesville, Florida, United States, 32608 Less <<
NCT02916745 Non-small Cell Lung Cancer (NS... More >>CLC) Lung Metastasis Less << Phase 1 Active, not recruiting May 2019 United States, Florida ... More >> University of Florida Gainesville, Florida, United States, 32611 United States, Georgia Southeastern Regional Medical Center Atlanta, Georgia, United States, 30265 United States, Illinois Alexian Brothers Hospital Network Elk Grove Village, Illinois, United States, 60007 United States, Oklahoma Southwestern Regional Medical Center Tulsa, Oklahoma, United States, 74133 United States, Washington Providence Medical Research Center Spokane, Washington, United States, 99204 United States, Wisconsin University of Wisconsin-Madison Madison, Wisconsin, United States, 53715 Canada, Ontario Toronto General Hospital Toronto, Ontario, Canada, M5G2C4 Less <<
NCT02153229 Epitheliod Malignant Pleural M... More >>esothelioma Less << Phase 2 Unknown - United States, New York ... More >> Rosewell Park Recruiting Buffalo, New York, United States, 14263 Contact: Kelly Dunn, MPH, CCRP    716-845-1300 ext 6537    kelly.dunn@roswellpark.org    Contact: Elongia Farrell, BA, CCRC    716-845-3114    elongia.farrell@roswellpark.org    Principal Investigator: Sai Yendamuri, MD          United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Sally McNulty, RN    215-662-7720    Sally.McNulty@uphs.upenn.edu    Contact: Keith Cengel, MD, PhD    855-216-0098    PennCancerTrials@emergingmed.com    Principal Investigator: Keith Cengel, MD, PhD Less <<
NCT03344861 Lung Cancer L... More >>ung Cancer Metastatic Less << Phase 1 Active, not recruiting March 2019 United States, California ... More >> Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Colorado University of Colorado Denver, Colorado, United States, 80045 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Cancer Treatment Centers of America/Southeastern Atlanta, Georgia, United States, 30265 United States, Illinois AMITA Health Alexian Brothers Medical Center Elk Grove Village, Illinois, United States, 60007 United States, Pennsylvania Dubois Medical Center DuBois, Pennsylvania, United States, 15801 United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington Providence Health & Services Spokane, Washington, United States, 99204 Less <<
NCT00540735 Cholangiocarcinoma Phase 3 Terminated(Big difficulties to... More >> enroll patients) Less << - France ... More >> UH Amiens Amiens, France, 80 000 UH Angers Angers, France, 49933 H Beaujon Clichy, France, 92 118 UH Henri Mondor Créteil, France, 94 010 UH Kremlin Bicêtre Le Kremlin Bicêtre, France, 94 275 UH Claude Huriez Lille, France, 59 037 Clinique Sainte Anne Lyon, France, 69 003 UH La Timone Marseille, France, 13 385 UH Marseille Nord Marseille, France, 13 915 H Metz-Thionville Metz, France, 57 038 UH Nantes Nantes, France, 44 000 Clinique du Trocadéro Paris, France, 75 116 UH Cochin Paris, France, 75 679 UH La Milétrie Poitiers, France, 86 021 UH Charles Nicolle Rouen, France, 76 031 UH Hôpital Civil Strasbourg, France, 67 091 UH Purpan Toulouse, France, 31 059 UH Rangueil Toulouse, France, 31 059 Less <<
NCT03678350 Malignant Mesothelioma ... More >> Non-Small Cell Lung Carcinoma Pleural Disorder Less << Phase 1 Not yet recruiting August 1, 2021 United States, New York ... More >> Roswell Park Cancer Institute Not yet recruiting Buffalo, New York, United States, 14263 Contact: Ask RPCI    800-767-9355    ASKRPCI@roswellpark.org    Principal Investigator: Saikrishna S. Yendamuri Less <<
NCT00984243 Lung Cancer Not Applicable Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00014066 Lung Cancer Phase 1 Completed - United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 Less <<
NCT01966809 Brain Tumor, Recurrent Phase 2 Active, not recruiting June 2021 United States, Wisconsin ... More >> Medical College of Wisconsin/ Froedtert Hospital Milwaukee, Wisconsin, United States, 53226 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.35mL

1.67mL

0.84mL

16.70mL

3.34mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories